Publication | Closed Access

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)

UrologyGenitourinary CancerMedicinePharmacologyClinical TrialsPharmacotherapyAnti-cancer AgentCancer TreatmentProstatic DiseaseOncologyMolecular OncologyExpansion Cohort